Painful Diabetic Neuropathy Drugs Market Research Report 2022 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Painful Diabetic Neuropathy Drugs Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 to 2030” report has been added to ResearchAndMarkets.com’s offering.

The Painful Diabetic Neuropathy Drugs Market is forecasted to grow at a CAGR of 7% during the forecast period of 2022 to 2030.

This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.

Painful diabetic peripheral neuropathy occurs in approximately 25% of patients with diabetes mellitus who have treated in the office sitting & sedentary lifestyle.

It typically causes burning pain, paresthesias & numbness in a stocking-glove pattern that progress from the feet & hands. Healthcare should carefully consider the patient’s goal, functional status & potential adverse effects of medication when choosing a treatment for painful diabetic peripheral neuropathy. Pregabalin and duloxetine are the two types of medications approved by the U.S. Food and Drug Administration for treating this disorder.

Peripheral Treatment trends the market

The treatment includes several medications such as, Anticonvulsants, Tricyclic antidepressants, Serotonin-norepinephrine reuptake inhibitors, Opioid-like medications, Topical medications, Selective serotonin reuptake inhibitors & Opioids. The medicines inhaled in this treatment costs about a range of 8$ – 560$.

They also have adverse effect as, nausea, headache, dizziness, peripheral edema, weight gain, constipation, Diarrhea, anxiety, vomiting, Somnolence, insomnia & so on. The range of patients causing adverse effect may vary from 5 % to 60 %. Various treatments for Painful Diabetic Neuropathy but the most effective & efficient is the peripheral treatment.

Increasing Prevalence Remains the Key Impeder

Diabetes has become one of the largest global health care diseases of the 21st century. According to the Centers for Disease Control and Prevention CDCP, the population prevalence of diabetes in the North America is approaching 10% and is increasing by 5% each year. The number of people with diabetes rose from 108 million in 1980 to 422 million in 2014.

Spread of diabetes has been emerging more rapidly in low & middle income countries than in high income countries. Approximately, 60 million people in the European Region are living with this disease, by straining the Region’s economies and health systems.

Prevalence of diabetes is increasing in the European Region has reached 10-12% of the population in some of the States. This increase is strongly associated with increasing trends towards overweight and obesity, unhealthy diets, physical inactivity and socioeconomic disadvantage. This trend is significantly increasing the prevalence of diabetic Neuropathy as well.

Key questions answered in this report

• What are the key micro and macro environmental factors that are impacting the growth of Painful Diabetic Neuropathy Drugs market?
• What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
• Estimated forecast and market projections up to 2030.
• Which segment accounts for the fastest CAGR during the forecast period?
• Which market segment holds a larger market share and why?
• Are low and middle-income economies investing in the Painful Diabetic Neuropathy Drugs market?
• Which is the largest regional market for Painful Diabetic Neuropathy Drugs market?
• What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
• Which are the key trends driving Painful Diabetic Neuropathy Drugs market growth?
• Who are the key competitors and what are their key strategies to enhance their market presence in the Painful Diabetic Neuropathy Drugs market worldwide?

Companies Mentioned

• Daiichi Sankyo Company Limited
• Eli Lilly and Company
• Johnson & Johnson Services Inc.
• Novartis AG
• Pfizer Inc.
• Grunenthal GmbH
• ViroMed Co.
• Collegium Pharmaceutical Inc.
• Acorda Therapeutics Inc.
• Zydus Pharmaceuticals
• Mallinckrodt Inc.
• Macleods Pharmaceuticals Ltd.
• Lupin Pharmaceuticals

For more information about this report visit https://www.researchandmarkets.com/r/vrh2bf

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900